Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esophageal Arterial Infusion vs Systemic Chemotherapy in ESCC
NCT05381636Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel and Cisplatin micelle injection (HA132) in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
nab-paclitaxelCisplatin micelle injection (HA132)
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05381636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381636.